| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Interest expense | - | - | 3,297 | 3,679 |
| Net loss | -114,190 | -42,281 | -73,238 | -106,964 |
| Basic net loss per common share (in dollars per share) | -5.08 | -1.9 | -3.32 | -4.92 |
| Basic weighted average number of common shares outstanding (in shares) | 22,482,502 | 22,207,017 | 22,091,314 | 21,745,929 |
| Diluted net loss per common share (in dollars per share) | -5.08 | -1.9 | -3.32 | -4.92 |
| Diluted weighted average number of common shares outstanding (in shares) | 22,482,502 | 22,207,017 | 22,091,314 | 21,745,929 |
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)